Streetbeat News

Earnings

EVER

EverQuote has provided its Q4 2023 outlook, expecting revenues to be in the range of $47M-$52M, compared to an estimate of $48.59M. The company also anticipates a Variable Marketing Margin of $16.5M-$18.5M and an Adjusted EBITDA of $(4.5)M-$(2.5)M. The company has not reconciled the non-GAAP measure Adjusted EBITDA to the GAAP measure net income due to inability to quantify certain amounts.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 9:14 pm

CLOV

Clover Health has revised its 2023 adjusted EBITDA outlook to a loss of $55M-$80M, an improvement from the previous estimate of a loss of $70M-$120M.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 9:14 pm

EVER

EverQuote reported Q3 losses of $(0.87) per share, missing the analyst consensus estimate of $(0.60) by 45%. This is a 335% decrease over losses of $(0.20) per share from the same period last year. The company reported quarterly sales of $55.01 million, beating the analyst consensus estimate of $52.84 million by 4.11%. This is a 46.71% decrease over sales of $103.22 million the same period last year.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 9:12 pm

AMPY

Amplify Energy reported Q3 2023 earnings per share (EPS) of $(0.34), missing the analyst consensus estimate of $0.16 by 312.5%. This represents a 129.06% decrease from the same period last year. However, the company's quarterly sales of $76.77 million beat the analyst consensus estimate of $74.50 million by 3.05%, despite being a 39.22% decrease from the same period last year.

Portfolio Pulse from vinayak@benzinga.com

November 06, 2023 | 9:12 pm

RCKT

Rocket Pharmaceuticals reported Q3 losses of $(0.75) per share, a 13.79% improvement from the $(0.87) per share loss reported in the same period last year.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 9:12 pm

NXPI

NXP Semiconductors (NASDAQ:NXPI) reported Q3 earnings of $3.70 per share, beating the analyst consensus estimate of $3.59 by 3.06%. However, this is a 2.89% decrease from the same period last year. The company also reported quarterly sales of $3.43 billion, beating the analyst consensus estimate of $3.40 billion by 0.94%, but this is a 0.44% decrease from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 9:11 pm

RCKT

Rocket Pharmaceuticals reported Q3 losses of $(0.75) per share, beating the analyst consensus estimate of $(0.81) by 7.41 percent. This is a 13.79 percent increase over losses of $(0.87) per share from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 9:11 pm

ACVA

ACV Auctions (NASDAQ:ACVA) reported Q3 2023 GAAP EPS of $(0.11), beating the estimate of $(0.15) by 26.67%. The company also reported quarterly sales of $119.01M, surpassing the estimate of $118.24M by 0.65%. Both figures represent an increase from the same period last year.

Portfolio Pulse from saritha@benzinga.com

November 06, 2023 | 9:11 pm

VRTX

Vertex Pharmaceuticals reported Q3 earnings of $4.08 per share, beating the analyst consensus estimate of $3.98 by 2.51%. This is a 1.75% increase from the same period last year. However, the company's quarterly sales of $2.48 billion missed the analyst consensus estimate of $2.50 billion by 0.64%, though it's a 6.43% increase from last year.

Portfolio Pulse from bharat@benzinga.com

November 06, 2023 | 9:11 pm

TASK

TaskUs has provided its Q4 and full year 2023 financial outlook. The company expects Q4 revenue to be between $225M-$227M, higher than the estimated $220.6M. For FY23, the revenue is projected to be $915M-$917M, surpassing the estimated $905.57M. The adjusted EBITDA margin is expected to be around 22.5% for Q4 and 23.3% for the full year. Free cash flow for 2023, excluding payment for earn-out consideration, is expected to be over $115M.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 9:11 pm